CSF2 and temporal arteritis: In a phase 2, randomized, double-blind, placebo-controlled trial, Mavrilimumab, a monoclonal antibody that blocks GM-CSF signaling, administered with a 26-weeks prednisone taper, significantly reduced the risk of flare and improved sustained remission rates compared with placebo plus a 26-weeks prednisone taper in patients with GCA (Cid et al., 2022).